Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. Chemotherapy. Duke University Medical Center, Durham, NC, United States

Survival: 2.9 months
Toxicity Grade: 3
Treatments: Biologic therapy
Country: United States
City/State/Province: Durham, NC
Hospital: Duke University Medical Center
Journal: Link
Date: 9/2010

This study involved a total of 23 glioblastoma multiforme patients who had progressed following previous treatment with bevacizumab. Patients were separated into 2 separate treatment groups. Group A consisted of 10 patients with a median age of 50.8 years and 70% male. Group B was made up of 13 patients with a median age of 52.4 years and 85% male.

Patients in group A were treated with the chemotherapeutic agent temozolomide and the biologic therapy agent bevacizumab, which is a monoclonal antibody that blocks cancer cell growth by targeting the vascular endothelial growth factor (VEGF) protein.

Patients in group B were treated with the chemotherapeutic agent etoposide and the biologic therapy agent bevacizumab.

The highest toxicity in group A was of grade 3, which was 1 case of grade 3 infection. In group B, there was 1 grade 4 toxicity reported, which was a case of neutropenia. Patients in this group also reported grade 2 and 3 fatigue (4 patients).

Median overall survival in group A was 12.6 weeks (2.9 months). For group B, the median overall survival was 19.0 weeks (4.4 months).

This study was partially supported by Genentech Pharmaceuticals, makers of Avastin (trade name for bevacizumab).

Correspondence: Dr. David A. Reardon; email:

E-mail to a Friend Email Physician More Information